In myeloma cells, bortezomib inhibits the functioning of the 26S proteasome and affects multiple molecular pathways, including oxidative stress, NF-κB, and DNA damage and repair pathways, as well as classical intrinsic (mitochondria-dependent) and extrinsic (death receptor-dependent) cell death cascades, inducing the apoptosis of myeloma cells (4, 18–20). Here, NFKB1 is linked to plasma cell myeloma.